clinical trial · NCT05197049
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC·phase3·active not recruiting·n = 350
Crohn DiseaseGuselkumab Dose 1Guselkumab Dose 2Guselkumab Dose 3Placebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
started
Jan 19, 2022
primary completion
Jul 4, 2023
completion
Oct 30, 2028
last updated
Jun 5, 2026
official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol